JP7247119B2 - slime remover - Google Patents

Description

TECHNICAL FIELD The present invention relates to a device for removing and preventing slime installed in a drainage system. In particular, it relates to a device for removing and preventing slime, which can be preferably applied to drains in bathrooms and the like. This application claims priority to Japanese Patent Application No. 2018-021982 filed on February 9, 2018, and the contents thereof are incorporated herein.

In kitchen sinks, bathroom drains, garbage baskets installed in these facilities, and in drain pipes, etc., slime due to microorganisms such as various bacteria and molds and their metabolites is likely to occur. Alternatively, a large number of drugs (slimy-removing drugs) for preventing the occurrence of slime, and devices (slimy-removing tools) for containing the drug to exert its effect have been proposed and used.
As such a slime removing tool, it is common to lock it on the upper part of the target equipment or equipment and exert its effect on the lower part than the locking position.
For example, Patent Document 1 describes a method in which a solution of the slime-controlling agent is spread over the slimy-generating wall surface by attaching a flexible belt-shaped object carrying a slimy-controlling agent to the upper part of the slime-generating wall surface. ing.
Patent Literature 2 describes a method in which a solid medicine is stored near the center of a lid-shaped slime remover, and a solution of the solid medicine is diffused in the outer peripheral direction and spread over the slimy-generating wall surface.
Patent Literature 3 describes a method in which solid medicine is stored in a ring-shaped container and placed near the outer circumference of a lid-shaped slime remover to spread the solution of the solid medicine on the wall surface where sliminess is generated. .
These slime removers are specifically designed with the drain of the kitchen sink and the garbage basket installed there in mind.

On the other hand, there are various types of bathroom drains. In particular, drainage outlets that are recessed from the washing area (sometimes called 'drainage basins' depending on the shape) have a variety of recessed shapes, and can be installed in any of these to demonstrate their effectiveness. A slime remover was not known. Therefore, unlike kitchen sink drains, bathroom drains need to be cleaned frequently to control slime. In particular, if the catch basin is covered with a lid or a perforated plate, it is difficult to prevent the growth of microorganisms due to poor ventilation and high humidity. There was also
In Patent Document 4, an antibacterial and antifungal structure whose surface is coated or plated with an antibacterial and antifungal material is placed on the inner bottom surface of the drainage basin, thereby exhibiting an antibacterial and antifungal effect in the drainage basin. method is described.

JP-A-11-247251 Japanese Patent Application Laid-Open No. 2001-240503 Japanese Patent Application Laid-Open No. 2001-317101 Japanese Patent Application Laid-Open No. 2014-5603

Regarding the antibacterial and antifungal structure of Patent Document 4, it is also described that if the upper part of the structure contacts the lid or perforated plate covering the drainage basin, it is effective against the lid or perforated plate. This method can only be applied to drains having a specific structure, and does not exhibit any particular effect on the peripheral wall of a drain pit. In addition, the production method is complicated in that the antibacterial/antifungal material is applied or plated, which is undesirable.
SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to provide a slime remover that is easy to manufacture, can be used for general bathroom drains, and is particularly effective for the entire depression around the drain.

As a result of intensive studies to solve the above problems, the inventors of the present invention have found that the frame of the slime remover is placed on the bottom of the drain port, and the drug storage section located above is supported and brought into contact with the wall surface of the recess. The inventors have found that the slime remover can solve the above problems, and completed the present invention.

Specifically, the present invention relates to the following inventions.
(1) A slime removal tool placed on the bottom of a drain to prevent slime,
(A) At least one drug storage section, which is located at the periphery of the slime remover when viewed from above when installed, has a drainage inlet and a drug solution outlet, and stores a solid drug for removing slime; and (B) having a frame structure made of at least partially plastically deformable material, which abuts against the bottom of the drain when installed and supports the drug storage section from below so that it can come into contact with the peripheral wall of the drain. Slime remover.
(2) The slime remover according to (1), which has a plurality of drug storage units.
(3) The slime remover according to (1) or (2), wherein the frame structure has a substantially annular shape when viewed from above when installed.
(4) The slime remover according to (2), wherein the frame structure connects a plurality of drug storage units in series.
(5) The slime remover according to any one of (1) to (4), which is intended for use in bathroom drains.

INDUSTRIAL APPLICABILITY According to the present invention, a slime remover that can be applied to various bathroom drains is provided.

1 is a perspective view of a slime removing tool (aspect 1) of the present invention. FIG. Fig. 2 is a plan view seen from above when the slime removing tool (aspect 1) of the present invention is installed. 1 is a side view of a slime removing tool (aspect 1) of the present invention. FIG. Fig. 2 is a perspective view of the slime removing tool (aspect 2) of the present invention; Fig. 10 is a plan view seen from above when the slime removing tool (aspect 2) of the present invention is installed. Fig. 2 is a side view of the slime removing tool (aspect 2) of the present invention;

The slime remover of the present invention is a slime remover to be placed on the bottom of a drain, and has at least one drug storage section and a frame structure.
The drug storage part in the present invention has a drainage inlet and a drug solution outlet, and has the purpose of storing a solid drug for removing slime. do.
The frame structure in the present invention is at least partially made of a material that is plastically deformable, and when installed, abuts against the bottom of the drain port and supports the drug storage unit from below so that it can come into contact with the peripheral wall of the drain port. is.
The slime remover of the present invention basically consists of the above two types of members, and other members are not particularly necessary, but they have other functions as long as they do not impair the effects of the present invention. A member may be included.
The slime remover of the present invention is placed on the bottom of the drain for the purpose of removing or preventing slime from the drain, the periphery of the drain, and/or the drain pipe. It has a remarkable effect on
Here, the "bottom part of the drainage port" refers to the lower end part of the drainage facility excluding the drainage pipe part, which is a tubular structure for flowing down the drainage. A perforated plate or a strainer is usually installed in this portion, and the slime remover of the present invention is used by being placed on the perforated plate or the rim portion at the upper end of the strainer or its surroundings.

(drug storage unit)
The drug storage part is located at the peripheral edge of the slime remover when viewed from above when installed. This is to allow the drug storage portion to come into contact with the peripheral wall of the drainage port. As described below, the frame structure supporting the drug storage section is made of a material that is at least partially plastically deformable, so that the drug storage section can be used by being deformed so as to come into contact with the peripheral wall of the drain port. becomes possible.
At least one drug storage section is sufficient, but it is preferable to have a plurality of drug storage sections in order to exhibit slime removal effects in each direction. , 4 or more. In addition, the outer shape of the drug storage section is not particularly limited, but it is preferable that it is elongated in a horizontal direction substantially perpendicular to the line extending from the center of the slime remover to each drug storage section. may be rectangular, oval, etc., and may be curved.
The drug storage unit is a container for storing a solid drug for removing slime, and essentially has at least a drainage inlet and a drug solution outlet. When drainage flows into the drainage port, part of this drainage flows into the drug storage section from the drainage inlet of the drug storage section. As a result, the solid chemical is dissolved, and the resulting chemical solution flows out from the chemical solution outlet, exhibiting a slimy-removing effect. It should be noted that although a mode in which the drainage inlet and the chemical solution outlet are also used is also included, it is preferable that both are installed separately in order to generate a water flow in the chemical storage section.
The position, number, size, and structure of the drainage inlet and the drug solution outlet are not particularly limited as long as there is no risk of the solid drug flowing out as it is.
When the outer shape of the drug storage section is elongated in a horizontal direction substantially perpendicular to the line extending from the center of the slime remover to each drug storage section, there are a plurality of liquid drug outlets along the longitudinal direction. is preferred. As a result, it is possible to exert the effect of removing slime over a wide area of the peripheral wall of the drain port. Further similarly, there may be multiple wastewater inlets along the length.
Regarding the positional relationship between the drainage inlet and the drug solution outlet, for example, the drainage inlet is provided on the upper surface and/or the upper side of the drug storage section, and is positioned lower than the drainage inlet on the bottom and/or side of the drug storage section. A chemical outlet may be provided. In this case, the drainage inlet preferably has a structure for suppressing the inflow of dust, and more specifically, preferably has a slit or mesh structure. In order to sufficiently dissolve the solid drug, the total opening area of the drug solution outlet is set so that the maximum amount of water that can be held in the drug holding part is 0.5 to 500 seconds, preferably 2 to 100 seconds, more preferably 5 to 5 seconds. It is preferably adjusted to flow out in 50 seconds. This can be achieved, for example, by reducing the opening area of the liquid medicine outflow port or by making it elongated like a slit.
Alternatively, a drainage inlet may be provided at the lower side of the drug storage section, and the drug solution outlet may be provided at a position equal to or higher than the drainage inlet of the drug storage section so as to prevent the flow of waste water. In this case, as the structure of the drainage inlet, there is a structure that opens upward, or a structure that provides a water receiving part for distributing a part of the drainage into the drug storage part and allows the drainage to flow into the drainage inlet from here. be. As for the structure of the chemical solution outlet into which waste water does not flow, there is a structure that opens downward or a structure that has a guide piece that guides the chemical solution downward.
The inside of the drug storage part may be a single space, or a partition may be provided to completely or partially divide the inside.
Materials for the drug storage section include metals, plastics, and the like, but plastics are preferable because they are easy to manufacture and can be molded integrally with the frame structure section.
In manufacturing the drug storage part, part or the whole of the drug storage part may be integrally formed with the frame structure part, or the frame structure part and the drug storage part may be formed separately and locked to each other to reduce the sliminess. It can also be used as a tool.

The slime remover of the present invention is used with a solid drug stored in the drug storage portion at least during use. Alternatively, the drug storage part may be supplied as a product containing solid drugs, either alone or in a state of being combined with the frame structure part. For this reason, it is necessary to manufacture the drug storage part with a structure capable of storing the solid drug after molding. Specifically, a method of molding the medicine supply part as two different members (at least one of which may be integrally molded with the frame structure part), and combining and fixing these two members after the solid medicine is contained, or a method of using a hinge. There is a method of integrally molding a medicine supply part consisting of two parts connected via a part, and closing and fixing a hinge part after storing a solid medicine. Examples of the fixing method include a method of fitting with claws and a method of melting and fixing. If a claw-fitting method is adopted, it is also possible to refill and re-use a new solid medicine after use of the solid medicine is completed.

(Solid medicine for slime removal)
The slimy-removing solid medicine used in the present invention is not particularly limited, but preferably has a shape that does not flow out of the medicine storage section as long as it has a slimy-removing effect. The state of a solid drug includes a hard-to-deform solid such as a tablet, a gel that has elasticity but no fluidity, and a solid that can change into such a gel by absorbing water.
The components of the slimy-removing solid agent used in the present invention are not particularly limited. containing and gradually releasing these drug components into the water are preferred. This release preferably occurs with the dissolution of the solid drug. In particular, when the release concentration of the drug decreases and the slime-removing effect decreases, the solid drug disappears, making it easier to determine when to replace the drug. preferable.
Examples of the drug component having the above-mentioned effect include chlorine-based disinfectants, non-bleaching powder antibacterial agents, antibacterial inorganic metals or compounds thereof, antibiotics, bacteria capable of removing slime, etc., preferably non-bleaching powder antibacterial agents. is an agent.

(chlorine disinfectant)
Examples of chlorine-based disinfectants that can be used in the present invention include sodium chlorite, bleaching powder, advanced bleaching powder, sodium hypochlorite, hypochlorous acid water, and the like.

(Non-bleaching powder type antibacterial agent)
As the non-bleaching powder antibacterial agent that can be used in the present invention, any agent can be used as long as it does not react with an acidic substance or the like to generate chlorine gas when used. Compounds known as antibacterial agents or antibacterial agents, and natural essential oils known to have antibacterial effects can be exemplified.

Antifungal agents or antibacterial agents that can be used in the present invention include, for example, 5-chloro-2-methyl-4-isothiazolin-3-one, 2-methyl-4-isothiazolin-3-one, 5-chloro-2 -n-octyl-4-isothiazolin-3-one, 4-chloro-2-n-octyl-4-isothiazolin-3-one, 4,5-dichloro-3-n-octyl-isothiazolin-3-one, 2 -n-octyl-4-isothiazolin-3-one, 1,2-benzisothiazolin-3-one, 2-methyl-4,5-trimethylene-4-isothiazolin-3-one, 2-methoxycarbonylbenzimidazole, 2 , 3,5,6-tetrachloro-4-methanesulfonylpyridine, 2-thiocyanomethylthiobenzothiazole, 2,2-dithio-bis-(pyridine-1-oxide), 3,3,4,4-tetrahydro Thiophene-1,1-dioxide, 4,5-dichloro-1,2-dithiolan-3-one, 5-chloro-4-phenyl-1,2-dithiolan-3-one, N-methylpyrrolidone, phenyl- (2-cyano-2-chlorovinyl) sulfone, methylene bisthiocyanate, 2-bromo-2-nitropropane-1,3-diol, 2,2-dibromo-2-ethanol, 2-bromo-4'-hydroxyacetophenone , dibromonitrile propionamide, 2-bromo-2-bromomethylglutaronitrile, sodium percarbonate, potassium persulfate, sodium perborate, orthophenylphenol, diphenyl, 2-isopropyl-5-methylphenol (thymol), 5-isopropyl -2-methylphenol (carbacrol), 4-isopropylphenol, 4-isopropyl-3-methylphenol, 3-isopropyl-5-methylphenol, thymol (2-isopropyl-5-methylphenol), parachlorometaxylenol, triclosan, diclosan, n-butyl parahydroxybenzoate, ethyl parahydroxybenzoate, methyl parahydroxybenzoate, benzalkonium chloride, benzethonium chloride, chlorohexidine hydrochloride, chlorohexidine gluconate, 2-pyridinethiol-1-oxide , 2-pyridinethiol-1-oxide zinc salt, 2-pyridinethiol-1-oxide sodium, N,N'-hexamethylenebis(4-carbamoyl-1-decylpyridinium bromide), 4,4'-(tetramethylene The Specific examples include amino)bis(1-decylpyridinium bromide) and the like.

Examples of natural essential oils that can be used in the present invention include cineole, hinokitiol, menthol, terpineol, borneol, nopol, citral, citronellal, citronellol, geraniol, linalool, dimethyloctanol, and thymol.

Furthermore, examples of the non-bleaching powder type antibacterial agent that can be used in the present invention include iodine type antibacterial agents, and among these, solid ones are particularly desirable. Examples of iodine antibacterial agents include 2,3,3-triiodoaryl alcohols, 2,3,3-triiodoaryl ethers, 2,3,3-triiodoarylazoles, 3-iodo-2 -propargylbutylcarbamate, 4-chlorophenyl(3-iodopropargyl)formal, iodopropargylazoles, diiodomethylparatolylsulfone, povidone iodine, benzyliodoacetate and paranitrobenzyliodoacetate.
The above non-bleaching powder antibacterial agents can be used singly or in combination of two or more.

(Inclusion compound type antibacterial agent)
These non-bleaching powder antibacterial agents can be guest compounds of polymolecular host compounds, such as 2-bromo-2-nitropropane-1,3-diol, 5-chloro-2-methyl-4-isothiazoline -3-one or the like is used as a guest compound to form an inclusion compound, which can be used as a non-bleaching powder type antibacterial agent.

In the present invention, the term "polymolecular host compound" refers to a compound that forms a crystalline complex (inclusion compound) having a regular arrangement and interacting with the guest antibacterial agent through intermolecular forces such as hydrogen bonding. The compound is not particularly limited as long as it is a compound having the above properties, and for example, the following compounds can be exemplified.
(1) Tetrakisphenols
(2) 1,1,6,6-tetraphenyl-2,4-hexadiyn-1,6-diol (3) 1,6-bis(2-chlorophenyl)-1,6-diphenylhexane-2,4- Diyne-1,6-diol (4) 1,1,4,4-tetraphenyl-2-butyne-1,4-diol (5) 2,5-bis(2,4,dimethylphenyl)hydroquinone (6) 1,1-bis(2,4,dimethylphenyl)-2-propyn-1-ol (7) 1,1,2,2-tetraphenylethane-1,2-diol (8) 1,1′-bi -2-naphthol (9) 9,10-diphenyl-9,10-dihydroxyanthracene (10) 1,1,6,6-tetra(2,4-dimethylphenyl)-2,4-hexadiyne-1,6- Diol (11) 9,10-bis(4-methylphenyl)-9,10-dihydroxyanthracene (12) 1,1-bis(4-hydroxyphenyl)cyclohexane (13) N,N,N',N'- Tetrakis(cyclohexyl)-(1,1′-biphenyl)-2-2′-dicarboxamide (14) 4,4′-sulfonylbisphenol (15) 4,4′-butylidenebis(3-methyl-6-tert- butylphenol)
(16) 2,2′-methylenebis(4-methyl-6-tert-butylphenol)
(17) 4,4′-thiobis(4-chlorophenol)
(18) 2,2′-methylenebis(4-chlorophenol)
(19) deoxycholic acid (20) cholic acid (21) α,α,α',α'-tetraphenyl-1,1'-biphenyl-2,2'-dimethanol (22) t-butylhydroquinone (23) ) 2,5-di-tert-butyl hydroquinone (24) granular cornstarch (25) 1,4-diazabicyclo-(2,2,2)-octane

Tetrakisphenols in the polymolecular host compound include, for example, 1,1,2,2-tetrakis(4-hydroxyphenyl)ethane, 1,1,2,2-tetrakis(3-fluoro-4- hydroxyphenyl)ethane, 1,1,2,2-tetrakis(3-chloro-4-hydroxyphenyl)ethane, 1,1,2,2-tetrakis(3-methyl-4-hydroxyphenyl)ethane, 1,1 , 2,2-tetrakis(3-methoxy-4-hydroxyphenyl)ethane, 1,1,2,2-tetrakis(3,5-dimethyl-4-hydroxyphenyl)ethane, 1,1,3,3-tetrakis (4-hydroxyphenyl)propane, 1,1,3,3-tetrakis(3-fluoro-4-hydroxyphenyl)propane, 1,1,3,3-tetrakis(3-chloro-4-hydroxyphenyl)propane, 1,1,3,3-tetrakis(3-methyl-4-hydroxyphenyl)propane, 1,1,3,3-tetrakis(3-methoxy-4-hydroxyphenyl)propane, 1,1,3,3- Tetrakis(3,5-dimethyl-4-hydroxyphenyl)propane, 1,1,4,4-tetrakis(4-hydroxyphenyl)butane, 1,1,4,4-tetrakis(3-fluoro-4-hydroxyphenyl) ) butane, 1,1,4,4-tetrakis(3-chloro-4-hydroxyphenyl)butane, 1,1,4,4-tetrakis(3-methyl-4-hydroxyphenyl)butane, 1,1,4 ,4-tetrakis(3-methoxy-4-hydroxyphenyl)butane, 1,1,4,4-tetrakis(3,5-dimethyl-4-hydroxyphenyl)butane, 1,1,5,5-tetrakis(4 -hydroxyphenyl)pentane, 1,1,5,5-tetrakis(3-fluoro-4-hydroxyphenyl)pentane, 1,1,5,5-tetrakis(3-chloro-4-hydroxyphenyl)pentane, 1, 1,5,5-tetrakis(3-methyl-4-hydroxyphenyl)pentane, 1,1,5,5-tetrakis(3-methoxy-4-hydroxyphenyl)pentane, 1,1,5,5-tetrakis ( Specific examples include tetrakis(hydroxyphenyl)alkanes such as 3,5-dimethyl-4-hydroxyphenyl)pentane.

The clathrate compound that can be used in the present invention is usually obtained by stirring a non-bleaching powder-based antibacterial agent as a guest and a host compound, optionally in the presence of water or an organic solvent, at room temperature to 100° C. for several minutes to several hours. It is easily obtained by reacting.

(Antibacterial inorganic metal or its compound)
An antibacterial inorganic metal or a compound thereof can be added to the slime control agent used in the present invention. It is not particularly limited as long as it is a component containing an inorganic metal having antibacterial properties, but it is preferably in a solid state, and is a particulate form in which the antibacterial inorganic metal itself or its oxide, chloride, nitrate, or sulfate is supported on a carrier. Things etc. are preferably selected.
Specific examples of carriers include phosphates (zirconium phosphate, calcium phosphate, etc.), metal oxides (silicon oxide, aluminum oxide, titanium oxide, zinc oxide, iron oxide, zirconium oxide, etc.), inorganic compounds (zeolite , clay minerals, silica gel, etc.). One or more of these carriers may be used.
Among them, a metal oxide carrier supporting an antibacterial inorganic metal oxide is more preferably selected from the viewpoint of supporting strength.
The antibacterial inorganic metal or the antibacterial inorganic metal in the compound thereof is not particularly limited as long as it is a metal having antibacterial properties, but silver, zinc, copper and the like are preferably selected. Silver is more preferably selected because of its antibacterial effect. One or more of these antibacterial inorganic metals may be used.
In addition, the actual products of antibacterial inorganic metals or compounds thereof are not particularly limited as long as they are commercially available. , a nanoparticle silver-based inorganic antibacterial agent sold under the trade name of Catalyst Chemical Industry Co., Ltd., or the like can be used.
The antibacterial inorganic metal-containing component can be used alone or in combination of two or more.
The amount of the antibacterial inorganic metal or its compound is preferably 0.0002% by mass or more in terms of silver element concentration, for example, in the case of a component containing silver. More preferably, it is 0.0002 to 0.005% by mass. At 0.0002% by mass or more, the antibacterial activity is improved, and at 0.005% by mass or less, the antibacterial activity is sufficient, which is the economically acceptable upper limit.
When the antibacterial inorganic metal or its compound is in the form of particles, the average particle size of dispersed particles in the composition is preferably 1 to 500 nm, more preferably 1 to 100 nm.
Here, the average particle size is a number average particle size and is measured by a light scattering method. If it is 500 nm or less, the dispersed state of the particles will be stable, and if it is 100 nm or less, the dispersed state of the particles will be more stable. In addition, the smaller the particle size, the more advantageous it is in terms of contact with bacteria.

(Bacteria that can remove slime)
Bacillus subtilis (genus Bacillus) and the like are specific examples of bacteria that can remove slime, and Bacillus natto and the like can be exemplified as Bacillus subtilis.

(other ingredients)
The solid drug used in the present invention is usually added with other ingredients necessary for formulation, except when it can be formulated alone. Other components include excipients, binders, dissolution modifiers, lubricants, surfactants, corrosion inhibitors, gels, antistatic agents, and other functional components.

(excipients, binders, dissolution modifiers)
Excipients, binders, solubility modifiers include fumaric acid, benzoic acid, adipic acid, succinic acid, sulfamic acid, dl-malic acid, citric acid, ascorbic acid, malonic acid, glycolic acid, C _10-24 saturated Organic acids such as fatty acids; Inorganic acids such as boric acid; Lactose; Sucrose; Glucose; Starches such as cornstarch; celluloses; inorganic salts such as sodium chloride, magnesium sulfate, potassium sulfate, calcium hydrogen phosphate, synthetic aluminum silicate, and magnesium trisilicate; polymer compounds such as polyvinyl alcohol, polyvinylpyrrolidone, sodium alginate, and gum arabic (powder) Sucrose fatty acid esters and the like can be mentioned, but among them, lactose; sucrose; glucose; starches such as cornstarch; celluloses such as crystalline cellulose, powdered cellulose, and hydroxypropyl cellulose; Alcohol, polyvinylpyrrolidone, dextrin, and the like are preferable because they can improve pressure moldability, and even if they are mixed with various detergents, they do not react to generate toxic gas or the like. Agents and dissolution modifiers can be added at a rate of 1 to 99% by mass with respect to the total amount of solid matter.

When calcium sulfate is used, calcium sulfate 0.5 hydrate is preferable from the point of view that moldability and solubility can be easily controlled. The β-type calcium sulfate is preferable to the α-type produced by pressure firing because it is less likely that the molded product will collapse due to water absorption, and this β-type calcium sulfate 0.5 hydrate is preferably used in combination with lactose or sucrose in terms of moldability and solubility control.

C _10-24 saturated fatty acids include stearic acid, lauric acid and the like.
These saturated fatty acids are used for the purpose of imparting lubricity during molding and at the same time improving the stability of the agent in water (preventing swelling and disintegration). It is used at a rate of up to 10% by mass.

Hydroxypropyl cellulose is one in which some or all of the hydroxyl groups of cellulose are substituted with —(CH ₂ CH(CH ₃ )—O) _m H (wherein m is an integer of 1 or more), and the degree of polymerization is , degree of substitution, etc. are not particularly limited. Examples of hydroxypropyl cellulose include hydroxypropyl cellulose HPC-SL and HPC-L (trade names, manufactured by Nippon Soda Co., Ltd.). The amount of hydroxypropylcellulose used in the present invention is preferably less than 5% by weight, more preferably 1-4% by weight, based on the total solids content of the solid drug.

(lubricant)
Examples of lubricants include magnesium stearate, calcium stearate, sodium stearate, sodium benzoate, orthoboric acid, silica, talc, and waxes. It can be used in a proportion of 0.01 to 1% by mass.

Talc is a hydrated silicate mineral of magnesium and has a composition of Mg ₃ Si ₄ O ₁₀ (OH) ₂ . In the present invention, it can be used in place of surfactants or in combination with surfactants. The content of talc is 0.1 to 10% by mass, preferably 0.5 to 3% by mass, based on the total weight of the solid medicine.

(Surfactant)
The surfactant used in the present invention is not particularly limited as long as it does not react with the antimicrobial component and has a melting point of 50°C or higher. If a surfactant with a melting point of 50° C. or less is used, there are problems such as the solid drug being easily dissolved by warm water, and the surfactant being easily bleed from the solid drug due to the rise in temperature in summer. Examples of surfactants having a melting point of 50° C. or higher include fatty acid alkanolamides such as coconut oil fatty acid monoethanolamide and lauric acid monoisopropanolamide; sorbitan fatty acid esters such as sorbitan stearate and sorbitan palmitate; and alkylalkanolamides. , sodium dialkylsulfosuccinate, sodium lauryl sulfate, polyoxyethylene stearyl ether, polyoxyethylene polyoxypropylene block polymers, and the like. Among them, coconut oil fatty acid monoethanolamide and sorbitan stearate are preferable surfactants.
Among these, commercially available products include the following. Examples of coconut oil fatty acid monoethanolamides include TOHOL N-120 (manufactured by Toho Chemical Industry Co., Ltd.) and Amisol CME (registered trademark, manufactured by Kawaken Fine Chemicals Co., Ltd.). Kawaken Fine Chemicals Co., Ltd.), Rheodor SP-S10V, S20V, S30V (registered trademark, manufactured by Kao Corporation) as sorbitan stearate, Sorbon S-60 (manufactured by Toho Chemical Industry Co., Ltd.), etc., and sorbitan palmitate Solbon S-40 (manufactured by Toho Chemical Industry Co., Ltd.), Emulgen 350 (registered trademark, manufactured by Kao Corporation) as polyoxyethylene stearyl ether, and Newpol PE-68 (manufactured by Kao Corporation) as polyoxyethylene polyoxypropylene block polymer registered trademark, manufactured by Sanyo Chemical Industries, Ltd.).
These can be used alone or in combination of two or more, but they affect the tableting properties during pressure molding, the solubility in water, the disintegration properties, and the stability of the antibacterial agent. should be determined in consideration of
The content of the surfactant is 0.1-10% by mass, preferably 0.5-3% by mass, based on the total mass of the solid drug.

As a compound for heat-melt mixing or kneading extrusion molding, a solid with a melting point of 40 to 100° C. is preferable, and various water-soluble polymers such as polyoxyethylene, polyoxyethylene polyoxy Surfactants such as propylene block polymers, polyoxyethylene alkylphenyl ethers, polyethylene glycol fatty acid esters, glycerin fatty acid esters, and polyoxyethylene alkyl ethers can be exemplified.

(corrosion inhibitor)
Examples of the corrosion inhibitor include alkylthiourea-based and triazole-based compounds, which can suppress corrosion of metal parts such as pipes.

(gel-like substance)
Examples of the gelling agent used as the gel include agar, gelatin, locust bean gum, sodium alginate, polyvinyl alcohol, gum arabic, gellan gum, amino acids, carboxymethylcellulose and its metal salts, carrageenan, and the like. .

(Antistatic agent)
By adding diatomaceous earth, clay sulfate, or the like as the antistatic agent, an antistatic effect can be imparted during molding.

(Other functional ingredients)
Compounds with other functional ingredients can be added. Other functional ingredients include bitter-tasting ingredients to prevent infants from eating them by mistake, deodorant ingredients to prevent bad odors from drains, aromatic ingredients, and coloring ingredients to improve design. can also be exemplified.

(Manufacturing and blending ratio of solid drugs)
The method for producing the solid drug used in the present invention is not particularly limited, but the drug used for slime removal and other ingredients are heated, melted and mixed, kneaded, extruded, pressure molded, or the like. . The pressure molding method is preferable because it can simultaneously form recesses and through holes depending on the model. A specific manufacturing method is, for example, as follows, but it is not necessary to be limited to this method.
First, each raw material is put into a Nauta mixer and mixed at room temperature (20 to 30° C.) for 30 to 60 minutes. The mixed raw materials are subjected to plate-like granulation through rolling rollers. It is roughly crushed once to manufacture bulk powder. The bulk powder is charged from the hopper of the tableting machine and tableted. Depending on the shape of the mold installed in the tableting machine, tablets having recesses and through holes are formed. Further, as a pressure tableting machine capable of forming recesses and through-holes, for example, HER2 rotary tableting machine manufactured by Kikusui Seisakusho Co., Ltd. can be used.

The mixing ratio of the drug used in the solid drug used in the present invention and other components is 1 to 99 parts by mass of the drug used for slime removal and 99 to 1 part by mass of the other components because of various usage conditions. The mixing ratio can be arbitrarily changed between parts, but preferably 5 to 20 parts by weight of the agent used for removing slime and 95 to 80 parts by weight of other components. Further, when a clathrate compound is used as a drug used for removing slime, the mixing ratio of 2 to 30 parts by mass of the clathrate compound and 98 to 70 parts by mass of other components is preferable.

(Shape of solid drug)
The shape of the solid drug may be spherical, tablet, cylindrical, rectangular parallelepiped, pyramidal, doughnut-shaped, or having a concave portion, and the size of the solid drug may be such that it can be accommodated in the drug storage section. Anything is possible. For example, one drug storage portion may store one solid drug adapted to the shape of the drug storage portion, or may store a plurality of smaller solid drugs. In particular, when the drug storage part has a shape that is long in one direction, it is preferable to store a plurality of solid drugs in series in the longitudinal direction, because manufacturing is easy and dissolution is easy during use.
The solid medicament is preferably a tablet having the shape of (A) and/or (B).
(A) A concave portion provided in the central portion of the top surface of the tablet and/or the central portion of the bottom surface of the tablet.
In this case, the depth of the recess is preferably 5 to 30% of the thickness of the tablet at the deepest point, or 3 to 20% of the diameter of the tablet.
(B) A through hole provided from the central portion of the upper surface of the tablet to the central portion of the bottom surface of the tablet.
In this case, the diameter of the through-hole is preferably 10-40% of the diameter of the tablet.
In particular, when the drug storage part has a structure in which water flows in a certain direction, the solid drug having the shape described above keeps the drug elution concentration from the initial stage of use to a concentration sufficient for long-term slime control. In addition, since the tablet disappears around the time when the drug elution concentration decreases, it is possible to easily determine when to replace the tablet.
As for the form of use of the solid drug, for example, a single columnar or doughnut-shaped drug may be used in accordance with the shape of the drug storage portion, but a large number of small particles may also be used. When a large number of small granules are used, in addition to using the same type, a plurality of different types of small solid medicaments, such as medicaments with different compounding components or medicaments with different solubility, can be used.

(Elution concentration of drug used for slime removal)
As for the elution concentration of the drug used in the present invention, it is preferable that the concentration of the bactericidal component is high at the initial stage, and that the concentration is above a certain level over a long period of time. In this case, the initial period is one day from the start of use, and the long-term period is at least 5 days, preferably at least 10 days, and more preferably at least 15 days from the start of use. Also, the elution concentration of the drug should be appropriately determined because the effective concentration varies depending on the type of drug used for slime removal, but it is preferably at least the minimum growth inhibitory concentration.
The elution concentration of the bactericidal component can be measured, for example, as follows. After filling the tablet for slime removal of the present invention into the drug storage part of the slime remover of the present invention, it is placed in the drain port, and then water with a water temperature of 37 to 42 ° C. is poured at a rate of 5 L / min per day. After 18 hours of treatment in which the water is turned on for 5 minutes and stopped for 55 minutes, it is left for 6 hours. This process is repeated every day. Every day, 10 seconds after the flushing water is finished, remove the slime remover, place it in a suitable container, and collect the attached water for 1 minute. The elution concentration of the sterilizing component in the collected water is measured. Depending on the bactericidal component, the measuring device differs. For example, when the agent used for slime removal is 5-chloro-2-methyl-4-isothiazolin-3-one (CMI), it can be measured by liquid chromatography. .

(frame structure)
At least a part of the frame structure part is made of a plastically deformable material, and is connected to the drug storage part. Also, when installed, it abuts against the bottom of the drain port and supports the drug storage section from below so that it can come into contact with the peripheral wall of the drain port. That is, it includes two members, the "drain port bottom abutment member" and the "drug storage section support member", as essential members. It should be noted that the frame structure may consist of a plurality of parts that are not directly connected to each other (i.e., connected to each other via the medicament containing parts), and may also be composed of two or more medicament containing parts. A member for simply connecting the parts ("drug storage part connecting member" to be described later) or the like may be included.
The material of the frame structure may be at least partially plastically deformable, and specifically includes metal, plastic, or a composite of these materials. Of these, plastic is preferable because it is easy to manufacture if it is molded integrally with the drug storage portion, and specific examples thereof include polyethylene, polypropylene, polyvinyl chloride, and the like. Moreover, the shape of the material is preferably linear or band-like.
The shape of the bottom of the drain port varies greatly depending on the product, and in many cases there is a protruding part, so when the slime remover is placed here, the slime remover hits the protruding part and tilts, etc., and a sufficient effect can be obtained. There is a possibility that it will not.
However, in the present invention, by making at least a part of the frame structure part plastically deformable, for example, if there is a protrusion at the bottom of the drain port, the frame structure part can be bent accordingly and installed stably. Also, the frame structure can be modified so that the drug storage section can easily come into contact with the peripheral wall.
If the frame structure is plastically deformable over its entire area, it is preferable because it can be applied to any shape of the drain port. However, it is not essential that the entire area be plastically deformable, and only a portion of the frame structure may be plastically deformable. For example, if a part of each drug storage part supporting member in the frame structure part is plastically deformable, the drug storage part can be brought into contact with the peripheral wall. In addition, if a part of the drain port bottom abutting member is made plastically deformable so that the portion (frame structure projecting member) can bypass the projecting portion of the drain port bottom, it can be stably placed on the drain port bottom. can be done.

The structure of the frame structure is not particularly limited, but a structure as simple as possible is preferable so as to facilitate plastic deformation. As such a simple structure, a structure in which a plurality of drug storage portions are connected in series in a ring (annular connection structure) is preferably exemplified. The frame structure is characterized in that it supports the drug storage section from below so that it can come into contact with the peripheral wall of the drain. This can be achieved by protruding upward on the peripheral edge side of the container support member, and by using at least a portion of the remaining portion as a drain port bottom abutting member. When the entire slime remover is installed and viewed from above, the frame structure has a shape such as a circle, an ellipse, or a rectangle, from which the medicine storage portion protrudes to the peripheral edge side.
As described above, in the annular connection structure, the frame structure protrudes upward on the peripheral edge side of the slime remover in the vicinity of the drug storage section. Therefore, if the projection is placed on the projection of the bottom of the drain, it can be installed stably without particularly deforming the bottom contacting member of the drain.
In addition, not only near the drug storage unit, but also a part of the frame structure is provided with a part that protrudes upward (frame structure protruding member), and the frame structure protruding member is also placed on the protruding part of the bottom of the drain port. You can also
Furthermore, when there are a plurality of drug storage units, not only the vicinity of a single drug storage unit, but also a member that connects two or more adjacent drug storage units (drug storage unit connection member) is used around the periphery. It may protrude upward on the edge side. In this case, the drug storage section connection member is not directly coupled to the drain port bottom abutment member, but is directly coupled only to the drug storage section. In addition, a structure in which an arm-shaped member protrudes from the vicinity of the center of the frame structure toward each drug storage section can be mentioned. If there are a plurality of drug storage units, the arm-like member must be branched. In this case, the vicinity of the center abuts the bottom of the drain port, and the tip of the arm-shaped member protrudes above it. The mode of branching is not particularly limited.
A frame structure having a more complicated structure is also possible. For example, an arm-like member supporting each drug storage part branches off from an annular member in the center part for contacting the bottom of the drain port. A structure in which the inner side of the annular member is mesh-like (also used as a hair catcher) is also conceivable. However, such a complicated structure is not very preferable because it takes time and money to manufacture, it is not easy to deform when installed, and slimy and dirt tends to remain on the branched part and the net-like part during use. For the above reasons, it is most preferable to have a structure in which a plurality of drug storage sections are connected in series in a ring-shaped manner, and are made of a material that does not branch (may be curved or bent).

Specific examples of the slime remover of the present invention will be described below with reference to the accompanying drawings, but the technical scope of the present invention is not limited thereto.

(Aspect 1)
Aspect 1 is an aspect having a ring-shaped connection structure including four drug storage portions 1 . 1 is a perspective view, FIG. 2 is a plan view seen from above during installation, and FIG. 3 is a side view.
The drug storage unit 1 has an elongated curved outer shape, and is arranged along the circumference around the center of the slime remover when viewed in plan view. The upper surface has five slit-shaped drainage inlets, and below that, from the peripheral side surface to the bottom surface, there are five slit-shaped chemical outlets. A structure such as a partition may be provided inside the drug storage unit 1 if necessary. A single or a plurality of solid medicines are stored in the medicine storage part 1 for use.
The frame structure part 2 is composed of drain port bottom contact members 5 (eight places), drug storage part support members 6 (eight places), and frame structure projecting members 7 (four places).
The drug storage section support member 6 is bent and coupled to the drain port bottom contact member 5 . The frame structure protruding member 7 is bent and connected to the drain bottom abutment member 5, and is further bent at two upper portions.
When viewed in plan view, the drain bottom abutment member 5 and the frame structure projecting member 7 are arranged along the circumference around the center of the slime remover. When viewed in a side view, the drain port bottom abutment member 5 is located below, from which the drug storage section support member 6 and the frame structure protruding member 7 protrude upward. is supported from below.
The frame structure part 2 is belt-shaped as a whole and can be plastically deformed in a direction perpendicular to the belt surface. It can be stably installed according to the shape of the bottom of the drain.

(Aspect 2)
Aspect 2 is an aspect having a ring-shaped connection structure including six drug storage units 1 . 4 is a perspective view, FIG. 5 is a plan view seen from above when installed, and FIG. 6 is a side view.
The drug storage part 1 has the same shape as in the case of the aspect 1, and when viewed in a plan view, it is arranged along the circumference around the center of the slime remover together with the drug storage part connecting member 8 described later. It is Of the six drug storage units 1, four of the drug storage units 1, excluding two facing each other, are connected by a drug storage unit connecting member 8, which will be described later, in two adjacent units.
The frame structure 2 includes drain port bottom abutment members 5 (four locations), drug storage section support members 6 (eight locations), and drug storage section connection members 8 (two locations).
The drug storage part support member 6 is bent and connected to the drain port bottom contact member 5 . The medicine containing portion connecting member 8 is directly connected to the medicine containing portion 1 at both ends thereof.
When viewed in a plan view, the drain port bottom contact member 5 is arranged along the circumference around the center of the slime remover. When viewed in a side view, the drain port bottom abutting member 5 is located below, and the medicine containing portion supporting member 6 protrudes upward from there, and the medicine containing portion supporting member 6 supports the medicine containing portion 1 from below. there is Each drug storage section connecting member 8 and the two drug storage sections 1 connected to both ends thereof are both located upward. Therefore, this aspect is suitable for use in a drain bottom having a large protrusion or a drain bottom having a complicated shape.
The frame structure part 2 is belt-shaped as a whole and can be plastically deformed in a direction perpendicular to the belt surface. It can be stably installed according to the shape of the bottom of the drain.

1 drug storage part 2 frame structure part 3 drainage inlet 4 drug solution outlet 5 drain port bottom contact member 6 drug storage part support member 7 frame structure protruding member 8 drug storage part connecting member

Claims (3)

A slime removal tool placed on the bottom of a drain to prevent slime,
(A) Four or more drug storage units, which are located at the peripheral edge of the slime remover when viewed from above when installed, have a drainage inlet and a drug solution outlet, and store a solid drug for removing slime; and (B) 4 or more drug storage units are connected in series, and consist of a linear or belt-like frame that is at least partially plastically deformable to match the shape of the drain, and abuts on the bottom of the drain when installed. and a slime removing tool having a frame structure for supporting the medicine storage part from below so that it can come into contact with the peripheral wall of the drain. 2. A slime remover according to claim 1 , wherein the frame structure has a substantially annular outer shape when viewed from above when installed. 3. The slime remover according to claim 1 or 2 , which is intended for use in bathroom drains.

Images